Indian Journal of Pharmaceutical Sciences最新文献

筛选
英文 中文
Effect of Huayu Qufu Shengji Decoction on Postoperative Pain and Wound Healing Time in Patients with Perianal Abscess 化瘀祛附生积汤对肛周脓肿术后疼痛及伤口愈合时间的影响
IF 0.5 4区 医学
Indian Journal of Pharmaceutical Sciences Pub Date : 2023-01-01 DOI: 10.36468/pharmaceutical-sciences.spl.688
Qijian Huang, Shuangming Lin, Jundi Zhong
{"title":"Effect of Huayu Qufu Shengji Decoction on Postoperative Pain and Wound Healing Time in Patients with Perianal Abscess","authors":"Qijian Huang, Shuangming Lin, Jundi Zhong","doi":"10.36468/pharmaceutical-sciences.spl.688","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.spl.688","url":null,"abstract":"Huang","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69621700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Application of PRECEDE-PROCEED Model in Health Education of Young and Middle-Aged with Lumbar Disc Herniation 前-后模式在中青年腰椎间盘突出症健康教育中的应用
IF 0.5 4区 医学
Indian Journal of Pharmaceutical Sciences Pub Date : 2023-01-01 DOI: 10.36468/pharmaceutical-sciences.spl.622
Z. Wang, Y. Zhong, Yan Dai, W. Wang, Wenli Su, Liuqing Wu, Mengwen Chen
{"title":"Application of PRECEDE-PROCEED Model in Health Education of Young and Middle-Aged with Lumbar Disc Herniation","authors":"Z. Wang, Y. Zhong, Yan Dai, W. Wang, Wenli Su, Liuqing Wu, Mengwen Chen","doi":"10.36468/pharmaceutical-sciences.spl.622","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.spl.622","url":null,"abstract":"","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69634330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic Potential of Pomegranate (Punica granatum Linn.) against Breast Cancer 石榴对乳腺癌的治疗潜力
IF 0.5 4区 医学
Indian Journal of Pharmaceutical Sciences Pub Date : 2023-01-01 DOI: 10.36468/pharmaceutical-sciences.spl.626
H. Tashkandi
{"title":"Therapeutic Potential of Pomegranate (Punica granatum Linn.) against Breast Cancer","authors":"H. Tashkandi","doi":"10.36468/pharmaceutical-sciences.spl.626","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.spl.626","url":null,"abstract":"","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69634380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Role of Serum C-C Motif Chemokine Ligand 2 Monocyte Chemotactic Activities in Patients with Non Small Cell Lung Cancer 血清C-C基序趋化因子配体2单核细胞趋化活性在非小细胞肺癌患者中的作用
IF 0.5 4区 医学
Indian Journal of Pharmaceutical Sciences Pub Date : 2023-01-01 DOI: 10.36468/pharmaceutical-sciences.spl.627
Z. Gao, C. Qian, Liang Zhang
{"title":"Role of Serum C-C Motif Chemokine Ligand 2 Monocyte Chemotactic Activities in Patients with Non Small Cell Lung Cancer","authors":"Z. Gao, C. Qian, Liang Zhang","doi":"10.36468/pharmaceutical-sciences.spl.627","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.spl.627","url":null,"abstract":"","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69634393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CCT2 Gene Expression in Hepatocellular Carcinoma and its Effect on the Biological Function of Hepatocellular Carcinoma Cells CCT2基因在肝癌中的表达及其对肝癌细胞生物学功能的影响
IF 0.5 4区 医学
Indian Journal of Pharmaceutical Sciences Pub Date : 2023-01-01 DOI: 10.36468/pharmaceutical-sciences.spl.666
Jiawen Lu, Y. Xiong, LI J.D.
{"title":"CCT2 Gene Expression in Hepatocellular Carcinoma and its Effect on the Biological Function of Hepatocellular Carcinoma Cells","authors":"Jiawen Lu, Y. Xiong, LI J.D.","doi":"10.36468/pharmaceutical-sciences.spl.666","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.spl.666","url":null,"abstract":":","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":"41 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69635064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antiproliferiative Activity of Biogenic Silver Nanoparticles Synthesized from Leonotis nepetifolia (L) on Human Cancer Cell lines 枸杞子合成的生物源银纳米颗粒对人癌细胞的抗增殖活性
IF 0.5 4区 医学
Indian Journal of Pharmaceutical Sciences Pub Date : 2023-01-01 DOI: 10.36468/pharmaceutical-sciences.1078
M. Harika, P. Radhika
{"title":"Antiproliferiative Activity of Biogenic Silver Nanoparticles Synthesized from Leonotis nepetifolia (L) on Human Cancer Cell lines","authors":"M. Harika, P. Radhika","doi":"10.36468/pharmaceutical-sciences.1078","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.1078","url":null,"abstract":"","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70215553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pristimerin Contributes to Gefitinib Resistance in Lung Cancer Cells by regulating microRNA-936 expression pritimerin通过调节microRNA-936表达参与肺癌细胞对吉非替尼的耐药
IF 0.5 4区 医学
Indian Journal of Pharmaceutical Sciences Pub Date : 2023-01-01 DOI: 10.36468/pharmaceutical-sciences.1075
Yuehui Juan, Yuehui Yu, L. Yi, L. Yang
{"title":"Pristimerin Contributes to Gefitinib Resistance in Lung Cancer Cells by regulating microRNA-936 expression","authors":"Yuehui Juan, Yuehui Yu, L. Yi, L. Yang","doi":"10.36468/pharmaceutical-sciences.1075","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.1075","url":null,"abstract":"To investigate the effect of pristimerin on gefitinib resistance in lung cancer cells and its regulation on microRNA-936. Lung cancer cell HCC827 was cultured in vitro , lung cancer gefitinib resistant cell HCC827/gefitinib resistant was established and HCC827/gefitinib resistant cells were randomly assigned to control group, pristimerin-L group, pristimerin-M group, pristimerin-H group, gefitinib group, gefitinib+pristimerin group, gefitinib+microRNA-negative control group, gefitinib+microRNA-936 group, gefitinib+pristimerin+anti-microRNA negative control group and gefitinib+pristimerin+anti-microRNA-936 group. 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide was used to detect the inhibition rate of cell proliferation, as well as the median half-maximal inhibitory concentration; the expression amount of microRNA-936 was detected by quantitative reverse transcription-polymerase chain reaction; cell migration and invasion were detected by transwell chamber assay. Compared with HCC827 cells, the proliferation inhibition rate of HCC827/gefitinib resistant cells was significantly lower and the half-maximal inhibitory concentration value was significantly higher (p<0.05); compared with the control group, the inhibition rate of cell proliferation was increased, the half-maximal inhibitory concentration value was decreased and the expression of microRNA-936 was increased (p<0.05) in pristimerin-L group, pristimerin-M group and pristimerin-H group; compared with the gefitinib group, the inhibition rate of cell proliferation was higher and the number of migration and invasion cells decreased in the gefitinib+pristimerin group (p<0.05); compared with the gefitinib+microRNA negative control group, the gefitinib+microRNA-936 group showed higher cell proliferation inhibition rate and lower cell number in migration and invasion (p<0.05); compared with the gefitinib+pristimerin+anti-microRNA negative control group, the cell proliferation inhibition rate decreased and the migration and invasion cell numbers increased in the gefitinib+pristimerin+anti-microRNA-936 group (p<0.05). Pristimerin may enhance cell gefitinib sensitivity by inhibiting proliferation, migration and invasion of gefitinib resistant cells in lung cancer by up regulating microRNA-936 expression.","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70215157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Kaempferol Promotes Apoptosis and Inhibited Autophagy in A549 Cells via MicroRNA-199/Mammalian Target of Rapamycin Axis 山奈酚通过MicroRNA-199/哺乳动物雷帕霉素轴靶蛋白促进A549细胞凋亡和抑制自噬
IF 0.5 4区 医学
Indian Journal of Pharmaceutical Sciences Pub Date : 2023-01-01 DOI: 10.36468/pharmaceutical-sciences.1089
Junjie Wang, Bo Han
{"title":"Kaempferol Promotes Apoptosis and Inhibited Autophagy in A549 Cells via MicroRNA-199/Mammalian Target of Rapamycin Axis","authors":"Junjie Wang, Bo Han","doi":"10.36468/pharmaceutical-sciences.1089","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.1089","url":null,"abstract":"Wang","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69606375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Formulation and Optimization of Propranolol Bilayer Tablets: A Potential Approach for Effective Management of Hypertension 心得安双层片的处方与优化:有效治疗高血压的潜在途径
IF 0.5 4区 医学
Indian Journal of Pharmaceutical Sciences Pub Date : 2023-01-01 DOI: 10.36468/pharmaceutical-sciences.1081
H. Mourya, N. Garud, R. Joshi, W. Akram, N. Singh
{"title":"Formulation and Optimization of Propranolol Bilayer Tablets: A Potential Approach for Effective Management of Hypertension","authors":"H. Mourya, N. Garud, R. Joshi, W. Akram, N. Singh","doi":"10.36468/pharmaceutical-sciences.1081","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.1081","url":null,"abstract":"The purpose of this investigation is to formulate and evaluate the antihypertensive drug propranolol hydrochloride sustained-release bilayer tablets. In this formulation, one layer provides a loading dose through the immediate release of the drug and the other layer provides a maintenance dose for up to 12 h through controlled release. Different quantities of polymers such as Kyron T-314, Hydroxypropyl methylcellulose-K4M, and ethyl cellulose were used to make bi-layer tablets by direct compression. The compatibility study of pharmaceutical excipients was conducted through Fourier transform infrared spectroscopy studies and no interaction was found. The pre-compression parameter for the angle of repose, bulk density, tapped density and compressibility index was assessed on the produced granules and the findings were good. The tablets were evaluated for the post-compression parameters for thickness, hardness, friability and in vitro release studies. In vitro dissolution study was approved out for 12 h using United States Pharmacopeia dissolution apparatus I using phosphate buffer of pH 1.2 and 6.8 as dissolution medium. Hydroxypropyl methylcellulose-K4M and ethylcellulose were used in combination in all formulations but optimized formulation propranolol hydrochloride tablet 4 showed a higher rate of drug release up to 12 h as compared to the other formulation and optimized formulations propranolol hydrochloride tablet 4 follows the Higuchi model with non-fickian diffusion based on regression coefficient of the kinetics data of cumulative drug release from the dosage form.","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69606690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inhibitory Effect of Ouabain on Resistance to Imatinib in Chronic Myeloid Leukemia K562/G01 Cells 瓦巴因对慢性髓系白血病K562/G01细胞对伊马替尼耐药的抑制作用
IF 0.5 4区 医学
Indian Journal of Pharmaceutical Sciences Pub Date : 2023-01-01 DOI: 10.36468/pharmaceutical-sciences.1129
Chang-Quan Sun, J. Liu, Shiqi Zhai, H. Liu, L. Peng, Jing Hu
{"title":"Inhibitory Effect of Ouabain on Resistance to Imatinib in Chronic Myeloid Leukemia K562/G01 Cells","authors":"Chang-Quan Sun, J. Liu, Shiqi Zhai, H. Liu, L. Peng, Jing Hu","doi":"10.36468/pharmaceutical-sciences.1129","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.1129","url":null,"abstract":"Ouabain has shown powerful anti-proliferation activities in various cancers, but its effect on imatinib-resistant chronic myeloid leukemia and toxicity on normal mice has not been investigated. Cell Counting Kit-8 assay was used to detect cytotoxicity and reversal effect of ouabain with different concentration (0.01 µM, 0.1 µM, 1.0 µM, 10 µM) on drug resistance of imatinib-resistant cell line of chronic myeloid leukemia (K562/G01 cell line). Flow cytometry was used to detect the apoptosis effect and cell cycle arrest. Hematological examination, biochemical examination and histological examination were used to detect sub-chronic toxicity of ouabain on healthy mice. In our present study, ouabain showed greatly inhibitory effect and significantly reduced half minimal inhibitory concentration of imatinib in K562/ G01 cells, an imatinib-resistant cell line of chronic myeloid leukemia, in a dose-and time-dependent manner, which implied that ouabain increased cell sensitivity to imatinib. Ouabain enhanced apoptosis induced by imatinib in K562/G01 cells not through cell cycle arrest. Animal experiments showed that there were no significant variances in hematological, liver function, kidney function parameters and organ histopathology of all mice groups. These data suggested that ouabain could be a potential agent to treat imatinib-resistant chronic myeloid leukemia for its powerful cytotoxicity as well as reversal effect, but further study is needed to find out its specific mechanism.","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69606862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书